JOHNSON & JOHNSON (JNJ)

Add a New Bears Reason Company: JOHNSON & JOHNSON (JNJ) Current price: Headline: (100 character max) Analysis: Cancel 50% agree 8 votes edit Generics eat into profits Top Contributor: Andrei Popovici | Created when NYSE:JNJ was $62.18 | Edit | History Like products of other major drugmakers, most of Johnson & Johnson's pharmaceutical products has been or will eventually be affected by generic medications. The U.S. patent for Risperdal, the company's most profitable drug, will expire in the end of 2007, and sales are likely to decline significantly after the loss of patent protection. (100 character max) Cancel 0% agree 2 votes edit FDA warnings are bad for business Top Contributor: Andrei Popovici | Created when NYSE:JNJ was $62.18 | Edit | History The FDA sends warning letters to manufacturers of medical devices when there is concern for product safety or reliability, creating negative publicity. In 2004, the FDA sent a warning letter to Johnson & Johnson's Cordis, identifying safety concerns in its manufacturing plants. This created negative publicity which has slowed the growth of this franchise until follow-inspections resolved the issue in 2006. (100 character max) Cancel 41% agree 12 votes edit Drug development is costly and its success is inherently risky Top Contributor: Andrei Popovici | Created when NYSE:JNJ was $62.18 | Edit | History Drug development is costly and its success is inherently risky. (100 character max) Cancel

Worried about pump and dump? We review changes for stock spam » read more

Want to make Wikinvest better? We need your help, contribute today » learn how

Do you write software? We are recruiting the best engineers » view jobs

Like Wikinvest? Spread the word — Tell your friends! » spread the word

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

About | Blog | Advertise | Jobs | Feedback | Help | Get involved